Pooled analysis of two large randomised phase III inhaled mannitol studies in cystic fibrosis

Journal of Cystic Fibrosis

Volumn 12, Issue 4, 2013, Pages 367-376

  Bilton, Diana ^a   Bellon, Gabriel ^b   Charlton, Brett ^c   Cooper, Peter ^d   De Boeck, Kris ^e   Flume, Patrick A ^f   Fox, Howard G ^c   Gallagher, Charles G ^g   Geller, David E ^h   Haarman, Eric G ⁱ   Hebestreit, Helge U ^j   Kolbe, John ^k   Lapey, Allen ^l   Robinson, Phil ^m   Wu, Jian ^c   Zuckerman, Jonathan B ⁿ   Aitken, Moira L ^o  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b UNIVERSITÉ LYON 1   (France)

^c Pharmaxis Ltd   (Australia)

^d SYDNEY CHILDREN'S HOSPITAL   (Australia)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^f MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^g ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^h FLORIDA STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

ⁱ VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^j UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^k UNIVERSITY OF AUCKLAND   (New Zealand)

^l MASSACHUSETTS GENERAL HOSPITAL   (United States)

^m UNIVERSITY OF MELBOURNE   (Australia)

ⁿ MAINE MEDICAL CENTER   (United States)

^o UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

more..

Author keywords

Airway mucociliary clearance; Clinical study; Cystic fibrosis; Dry powder inhalers; FEV1; Mannitol dry powder

Indexed keywords

MANNITOL;

ADOLESCENT; ADULT; ARTICLE; CHILD; CONTROLLED STUDY; COUGHING; CYSTIC FIBROSIS; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FORCED EXPIRATORY VOLUME; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; CHILD; CYSTIC FIBROSIS; FEMALE; HUMANS; MALE; MANNITOL; MIDDLE AGED; YOUNG ADULT;

EID: 84878360064     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2012.11.002     Document Type: Article

References (30)

1. Henke M.O., Ratjen F. Mucolytics in cystic fibrosis. Paediatr Respir Rev 2007, 8:24-29.
2. Sanders D.B., Bittner R.C., Rosenfeld M., Hoffman L.R., Redding G.J., Goss C.H. Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am J Respir Crit Care Med 2010, 182:627-632.
3. Allison R.G. Dietary sugars in health and disease. IV. Mannitol. NTIS PB Report (PB-221 211) 1979, 94.
4. Robinson M., Daviskas E., Eberl S., Baker J., Chan H.-K., Anderson S.D., et al. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. Eur Respir J 1999, 14:678-685.
5. Daviskas E., Anderson S.D., Brannan J.D., Chan H.-K., Eberl S., Bautovich G. Inhalation of dry powder mannitol increases mucociliary clearance. Eur Respir J 1997, 10:2449-2454.
6. Daviskas E., Anderson S.D., Eberl S., Chan H.-K. Inhalation of dry powder mannitol improves clearance of mucus in patients with bronchiectasis. Am J Respir Crit Care Med 1999, 159:1843-1848.
7. Daviskas E., Anderson S.D., Eberl S., Chan H.-K., Young I.H. The 24-hr effect of mannitol on the clearance of mucus in patients with bronchiectasis. Chest 2001, 119:414-421.
8. Daviskas E., Anderson S., Young I.H. Inhaled mannitol changes the sputum properties in asthmatics with mucus hypersecretion. Respirology 2007, 12:683-691.
9. Daviskas E., Anderson S.D., Eberl S., Chan H.K., Young I.H., Seale J.P. Effects of terbutaline in combination with mannitol on mucociliary clearance. Eur Respir J 2002, 20:1423-1429.
10. Jaques A., Daviskas E., Turton J.A., McKay K., Cooper P., Stirling R.G., et al. Inhaled mannitol improves lung function in cystic fibrosis. Chest 2008, 133:1388-1396.
11. Goldman M., Daviskas E., Turton J.A., Anderson S.D. Inhaled mannitol improves lung function assessed by forced oscillation in a placebo controlled trial in patients with bronchiectasis. Eur Respir J 2004, 24:470s-471s. [P2943].
12. Daviskas E., Turton J.A., Anderson S.D., Lassig A., Charlton B. A placebo controlled trial with inhaled mannitol improves health related quality of life in patients with bronchiectasis. Eur Respir J 2004, 24:707s. [P4338].
13. Bilton D. A randomised, placebo-controlled trial of inhaled mannitol in patients with bronchiectasis. Am J Respir Crit Care Med 2009, 179(E21):A3221.
14. Bilton D., Robinson P., Cooper P., Gallagher C.G., Kolbe J., Fox H., et al. Inhaled dry powder mannitol in cystic fibrosis: an efficacy and safety study. Eur Respir J 2011 Nov, 38(5):1071-1080.
15. Aitken M.L., Bellon G., De Boeck K., Flume P.A., Fox H., Geller D.E., et al. Long-term inhaled dry powder mannitol in cystic fibrosis: an international randomized study. Am J Respir Crit Care Med 2012, 185:645-652.
16. Daviskas E., Anderson S.D., Eberl S., Young I.H. Effect of increasing doses of mannitol on mucus clearance in patients with bronchiectasis. Eur Respir J 2008, 31(4):765-772.
17. Daviskas E., Anderson S.D., Gomes K., Briffa P., Cochrane B., Chan H.-K., et al. Inhaled mannitol for the treatment of mucociliary dysfunction in patients with bronchiectasis: effect on lung function, health status and sputum. Respirology 2005, 10:46-56.
18. Corey M., Edwards L., Levison H., Knowles M. Longitudinal analysis of pulmonary function decline in patients with cystic fibrosis. J Pediatr 1997, 131:809-814.
19. Milla C.E., Warwick W.J. Risk of death in cystic fibrosis patients with severely compromised lung function. Chest 1998, 113(5):1230-1234.
20. Mayer Hamblett N., Rosenfeld M., Goss C., Aitken M.L. Developing cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality. Am J Respir Crit Care Med 2002, 166:1550-1555.
21. Fuchs H.J., Borowitz D.S., Christiansen D.H., Morris E.M., Nash M.L., Ramsey B.W., et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med 1994, 331:637-642.
22. Cystic Fibrosis Patient Registry Data US Cystic Fibrosis Foundation Patient Registry 2010, Bethesda MD 2010.
23. Britto M.T., Kotagal U.R., Hornung R.W., Atherton H.D., Tsevat J., Wilmott R.W. Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis. Chest 2002, 121:64-72.
24. Ramsey B.W., Pepe M.S., Quan J.M., Otto K.L., Montgomery A.B., Williams-Warren J., et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999, 340:23-30.
25. Teper A., Jaques A., Charlton B. Inhaled mannitol in patients with cystic fibrosis: a randomised open-label dose response trial. J Cyst Fibros 2011, 10:1-8.
26. Konstan M.W., Flume P.A., Kappler M., Chiron R., Higgins M., Brockhaus F., et al. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: the EAGER trial. J Cyst Fibros 2011, 10(1):54-61.
27. McCoy K.S., Quittner A.L., Oermann C.M., Gibson R.L., Retsch-Bogart G.Z., Montgomery A.B. Inhaled aztreonam lysine is effective in intensively-treated patients with cystic fibrosis. Am J Respir Crit Care Med 2008, 178:921-928.
28. Elkins M.R., Robinson M., Rose B.R., Harbour C., Moriarty C.P., Marks G.B., et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006, 354(3):229-240.
29. Pettit R.S., Johnson C.E. Airway-rehydrating agents for the treatment of cystic fibrosis: past, present, and future. Ann Pharmacother 2011, 45(1):49-59.
30. Allison K.R., Brynildsen M.P., Collins J.J. Metabolite-enabled eradication of bacterial persisters by aminoglycosides. Nature 2011, 473(7346):216-220.